Lifecore Biomedical acquired by Webster Equity Partners for $6.28 per share plus CVRs

Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for $6.28 per share in cash plus contingent value rights, valuing the deal up to $663.7 million. The cash consideration represents a 49.5% premium to the last closing price. Stock resumed trading and surged 58% to $6.62. 149 clean stories shaped this window, with sentiment strongly bearish at 26/100. Also in focus: Nvidia expands buyback to $235B, China signals possible RTX Pro 5500 purchases, launches AI safety platform.